You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

MIFEPREX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Mifeprex, and when can generic versions of Mifeprex launch?

Mifeprex is a drug marketed by Danco Labs Llc and is included in one NDA.

The generic ingredient in MIFEPREX is mifepristone. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the mifepristone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Mifeprex

A generic version of MIFEPREX was approved as mifepristone by GENBIOPRO on April 11th, 2019.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for MIFEPREX?
  • What are the global sales for MIFEPREX?
  • What is Average Wholesale Price for MIFEPREX?
Summary for MIFEPREX
Drug patent expirations by year for MIFEPREX
Recent Clinical Trials for MIFEPREX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
RTI InternationalPhase 1
Rochester General HospitalPhase 1
Nova Southeastern UniversityPhase 1

See all MIFEPREX clinical trials

US Patents and Regulatory Information for MIFEPREX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Danco Labs Llc MIFEPREX mifepristone TABLET;ORAL 020687-001 Sep 28, 2000 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for MIFEPREX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Danco Labs Llc MIFEPREX mifepristone TABLET;ORAL 020687-001 Sep 28, 2000 ⤷  Sign Up ⤷  Sign Up
Danco Labs Llc MIFEPREX mifepristone TABLET;ORAL 020687-001 Sep 28, 2000 ⤷  Sign Up ⤷  Sign Up
Danco Labs Llc MIFEPREX mifepristone TABLET;ORAL 020687-001 Sep 28, 2000 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for MIFEPREX

See the table below for patents covering MIFEPREX around the world.

Country Patent Number Title Estimated Expiration
Spain 2012197 PROCEDIMIENTO PARA PREPARAR DERIVADOS 17BETA-OH-19-NOR-ESTEROIDES SUSTITUIDOS EN 17ALFA. (Novel 17 beta -hydroxy-19-nor-steroids) ⤷  Sign Up
South Korea 840000581 ⤷  Sign Up
Ireland 820044 ⤷  Sign Up
Ireland 842597 ⤷  Sign Up
Germany 3844408 In 17 alpha-Stellung substituierte 17ß-Hydroxy-19-norsteroid-Derivate, deren Herstellungsverfahren, und diese enthaltende pharmazeutische Zusammensetzungen ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for MIFEPREX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0057115 SPC/GB93/030 United Kingdom ⤷  Sign Up
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.